Pfizer currently offers a dividend yield of approximately 6.7%, one of the highest in the pharmaceutical sector. This elevated yield reflects investor concerns over waning demand for its COVID-19 vaccine and Paxlovid treatment, as well as patent expiries on key products. Nonetheless, the stock trades at a forward price-to-earnings ratio of roughly 8.7, below its five-year average of 9.7, suggesting that the market may be underestimating the company’s ability to sustain cash flow and dividend payments through its broad product portfolio.

In late 2025, Pfizer entered into a licensing agreement with YaoPharma to develop a novel GLP-1 receptor agonist currently in early-stage clinical trials. Concurrently, the company has increased R&D spend in oncology by 12% over the past year, allocating an additional $1.2 billion to clinical programs targeting solid tumors. These initiatives are designed to offset declines in COVID-related revenues and bolster long-term growth through diversified therapeutic pipelines.

Pfizer recently completed the sale of its 11.7% equity stake in ViiV Healthcare for $1.875 billion. The transaction closed in January 2026 and enabled Pfizer to redeploy capital toward higher-margin R&D and share repurchases. Following the sale, partner Shionogi increased its holding to 21.7%, while Pfizer has earmarked approximately $1.3 billion of the proceeds for debt reduction and up to $500 million for opportunistic share buybacks in the current quarter.